-
Zejing Pharmaceutical: Disclosure of research and development progress of Donafinil tosylate tablets
Time of Update: 2021-09-05
On the 16th, Zejing Pharmaceutical issued an announcement stating that Donafinil Tosylate Tablets is a multi-center, randomized, double-blind, placebo-controlled treatment of locally advanced/metastatic radioiodine refractory differentiated thyroid cancer (RAIR-DTC) The Phase III clinical trial (code name: ZGDD3) carried out a preset interim analysis, and the Independent Data Monitoring Committee (IDMC) reviewed the results and determined that the effectiveness and safety results were in line with expectations .
-
Treat chronic hepatitis B! GSK antisense oligonucleotide drug approved for clinical use
Time of Update: 2021-09-05
Therefore, after stopping the drug, the recurrence rate of chronic hepatitis B is very high,GSK3228836 is an antisense oligonucleotide that can specifically recognize the mRNA used to express viral antigens (pathogenic proteins) in liver cells infected with HBV, and inactivate viral mRNAs by mobilizing the liver’s own enzymes to inhibit viral proteins HBsAg levels in order to achieve the functional purpose of curing hepatitis B .
-
Eisai Perampanel approved for 2 new indications
Time of Update: 2021-09-05
In September 2019, Perampanel was approved for marketing in China for the add-on treatment of patients with partial epilepsy (with or without secondary generalized seizures) aged 12 years and older .
-
BeiGene's PD-1 new indication is clinically approved
Time of Update: 2021-09-05
On January 12, 2021, BeiGene and Novartis reached a cooperation and licensing agreement to develop, Production and commercialization of the anti-PD-1 antibody Bezean (Tilelizumab), with a total transaction value of up to 2.
-
Huabei Pharmaceutical's new rabies drug, omiltivizumab, has not been approved for large specifications
Time of Update: 2021-09-05
Article source: Medical Rubik's Cube InfoOn August 12, North China Pharmaceutical submitted a new class 1 recombinant human anti-rabies monoclonal antibody (ormutivimab) for the passive immunization of rabies virus-exposed patients.
-
Rongchang Biotechnology is favored by American ADC giants!
Time of Update: 2021-09-05
Rongchang Bio-Vidicuzumab Research and Development ProgressIn the sci-tech innovation board prospectus, Rongchang Biological expects to complete the phase III confirmatory clinical trial of vedicitumumab for the treatment of gastric cancer in 2026, ensuring that it is fully approved for marketing .
-
Lymphoma Express: The first XPO1 inhibitor to treat r/r DLBCL; how is CAR-T treatment progress
Time of Update: 2021-09-05
SADAL research key data (source: NextMed database)OS subgroup analysis (Source: J Hematol Oncol)The results show that for patients with relapsed or refractory DLBCL who have previously received ≥2 lines of chemoimmunotherapy, the oral monotherapy Selinesor can induce sustained anti-tumor activity, and adverse reactions can be controlled .
-
Candidates for licensed pharmacists can sign up
Time of Update: 2021-09-05
The examination is based on the 2021 pharmacist vocational qualification examination pharmacy management and regulations subject outline .
Attachment: 2021 national licensed pharmacist vocational qualification examination outline, pharmaceutical management and regulatory subject adjustment content
-
Research progress in the development of long-acting technologies for protein and peptide drugs (Part 1)
Time of Update: 2021-09-05
To improve the stability of protein and peptide drugs, prolong the half-life in the body, and make it long-acting .
-
Eli Lilly Baritinib receives FDA emergency authorization for single-drug treatment of COVID-19 hospitalized patients
Time of Update: 2021-09-05
Article Source: Immediate Medicine NewsToday, the US FDA revised the emergency use authorization (EUA) of baricitinib (brand name Olumiant), and now authorizes baritinib to be used alone for the treatment of assisted oxygen supply, non-invasive or invasive mechanical ventilation or extracorporeal membrane lung Oxygenation (ECMO) hospitalized adults and pediatric COVID-19 patients 2 years of age or older .
-
Deqi Pharmaceuticals and De Ruizhi Pharmaceutical Co., Ltd. to Promote the Research and Development of Small Molecule Drugs for Difficult Drug Targets
Time of Update: 2021-09-05
On August 9, Deqi Pharmaceuticals and De Ruizhi Pharmaceuticals announced a cooperation to jointly promote the research and development of small molecule anti-tumor first-in-class drugs .
Up to now, De Rui Zhi Yao has made a contribution to the development of a pre-clinical drug candidate of De Qi Pharmaceutical .
-
China Food and Drug Administration: A batch of Philips Jinkewei medical devices is being recalled
Time of Update: 2021-09-05
On August 6, the State Food and Drug Administration issued an announcement to notify Philips Kingway (Shenzhen) Industrial Co.
Details are as follows:Philips Kingway (Shenzhen) Industrial Co.
Philips Kingway (Shenzhen) Industrial Co.
voluntarily recalled its electrocardiograph .
-
Shanghai Huilun "Serodosin" was approved for listing
Time of Update: 2021-09-05
A randomized, double-blind, placebo and positive drug controlled phase III clinical trial conducted by Japanese scholars included 457 BPH patients, divided into xerodoxine group (N=176) and tamsulosin group (N= 192) and placebo group (N=89), the results showed that xerodoxine improved the total IPSS score significantly better than placebo (P <0.
-
Roxastat, a targeted Nobel pathway, was approved by the European Commission for listing
Time of Update: 2021-09-05
Astellas Pharma and FibroGen today announced that the European Commission (EC) has approved the marketing of Evrenzo (roxadustat) for the treatment of adult patients with chronic kidney disease (CKD) related symptomatic anemia .
Retrieved 2021-08-20, from https:// releases/astellas-receives-european-commission-approval-for-first-in-class-evrenzo-roxadustat-for-adult-patients-with-symptomatic-anemia-of-chronic-kidney-disease-301359297.
-
Variant strains ravaging mRNA vaccines or spawning 470 billion years of sales market domestic layout of enterprises at a glance
Time of Update: 2021-09-05
mRNA new crown vaccine year "absorbs gold" or exceeds 470 billionmRNA new crown vaccine year "absorbs gold" or exceeds 470 billionAt present, the main R&D and sales companies of the global mRNA COVID-19 vaccine are:Moderna of the United States; Pfizer/Germany BioNTech (owns global market rights outside of Greater China); Fosun Pharma/Germany BioNTech (owns greater Emergency use authorization) .
-
Venlafaxine Hydrochloride Sustained-Release Capsules, a subsidiary of Renfu Pharmaceutical, obtained FDA approval
Time of Update: 2021-09-05
On August 9, Renfu Medicine issued an announcement stating that its holding subsidiary, Yichang Renfu, had received the US FDA’s approval number for venlafaxine hydrochloride sustained-release capsules, which are suitable for various types of depression, including those accompanied by anxiety.
-
Pharmaceutical stocks plummeted. Hengrui, Mindray, Changchun Hi-tech, WuXi and others staged a battle royale!
Time of Update: 2021-09-05
On the whole, this performance is as stable as ever, but because of careful comparison, the company's operating income and main business gross profit margin are not as good as market expectations, plus the investment indicator-Hillhouse Capital reduced its holdings in the second quarter Half of the shares are regarded as a major negative .
-
Huabei Pharmaceutical: Withdrawal of registration application for recombinant human anti-rabies monoclonal antibody injection
Time of Update: 2021-09-05
Recently, based on research and analysis of clinical needs, market conditions, R&D costs and other factors, the subsidiary new drug company voluntarily withdrew the registration application of recombinant human anti-rabies monoclonal antibody injection 500 IU/2.
-
Tasly Launches Phase III Study of Compound Danshen Dripping Pills in the Treatment of Acute Altitude Sickness in the United States
Time of Update: 2021-09-05
Article source: Medical Rubik's Cube InfoRecently, Tasly registered a Phase III clinical study on the prevention and treatment of acute altitude sickness (AMS) with T89 (Compound Danshen Dripping Pills) on the American Clinical Network .
-
Ma Yinglong Pharmaceutical Appoints Liu Pingan as Deputy General Manager
Time of Update: 2021-09-05
On August 20, Ma Yinglong Pharmaceutical issued an announcement stating that the company held the twelfth meeting of the tenth board of directors on August 19 and passed the "Proposal on the Appointment of Senior Executives .
Liu Ping’an was appointed as the company’s deputy general manager .
